-
Je něco špatně v tomto záznamu ?
Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test
JJ. Michiels, P. Smejkal, M. Penka, A. Batorova, T. Pricangova, U. Budde, I. Vangenechten, A. Gadisseur,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
NLK
ProQuest Central
od 1995-01-01
Medline Complete (EBSCOhost)
od 1995-01-01
Health & Medicine (ProQuest)
od 1995-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1995
PubMed
27443694
DOI
10.1177/1076029616647157
Knihovny.cz E-zdroje
- MeSH
- desmopresin farmakologie MeSH
- diferenciální diagnóza * MeSH
- lidé MeSH
- multimerizace proteinu MeSH
- mutace MeSH
- von Willebrandova nemoc, typ 1 diagnóza MeSH
- von Willebrandova nemoc, typ 2 diagnóza MeSH
- von Willebrandův faktor analýza genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
The European Clinical Laboratory and Molecular (ECLM) classification of von Willebrand disease (vWD) is based on the splitting approach which uses sensitive and specific von Willebrand factor (vWF) assays with regard to the updated molecular data on structure and function of vWF gene and protein defects. A complete set of FVIII:C and vWF ristocetine cofactor, collagen binding, and antigen, vWF multimeric analysis in low- and medium-resolution gels, and responses to desmopressin (DDAVP) of FVIII:C and vWF parameters are mandatory. The ECLM classification distinguishes recessive types 1 and 3 vWD from recessive vWD 2C due to mutations in the D1 and D2 domains and vWD 2N due to mutations in the D'-FVIII-binding domain of vWF. The ECLM classification differentiates between mild vWD type 1 with variable penetrance of bleedings from symptomatic dominant type 1 vWD secretion defect and/or clearance defect with normal vWF multimers versus vWD 1M and 2M with normal or smeary vWF multimers in low- and medium-resolution gels. High-quality multimeric analysis of vWF in medium-resolution gels based on a DDAVP challenge test clearly delineates and distinguishes each of the dominant type 2 vWDs 1/2E, 2M, 2B, 2A, and 2D caused by vWF gene mutations in the D3 multimerization domain, loss or gain-of-function mutations in the glycoprotein Ib receptor A1 domain, gene mutations in the A2 proteolytic domain, and the C-terminal dimerization domain, respectively.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18025344
- 003
- CZ-PrNML
- 005
- 20180713102621.0
- 007
- ta
- 008
- 180709s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/1076029616647157 $2 doi
- 035 __
- $a (PubMed)27443694
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Michiels, Jan Jacques $u 1 Goodheart Institute in Nature Medicine & Health, Blood Coagulation and Vascular Medicine Center, Rotterdam, The Netherlands. 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium.
- 245 10
- $a Diagnostic Differentiation of von Willebrand Disease Types 1 and 2 by von Willebrand Factor Multimer Analysis and DDAVP Challenge Test / $c JJ. Michiels, P. Smejkal, M. Penka, A. Batorova, T. Pricangova, U. Budde, I. Vangenechten, A. Gadisseur,
- 520 9_
- $a The European Clinical Laboratory and Molecular (ECLM) classification of von Willebrand disease (vWD) is based on the splitting approach which uses sensitive and specific von Willebrand factor (vWF) assays with regard to the updated molecular data on structure and function of vWF gene and protein defects. A complete set of FVIII:C and vWF ristocetine cofactor, collagen binding, and antigen, vWF multimeric analysis in low- and medium-resolution gels, and responses to desmopressin (DDAVP) of FVIII:C and vWF parameters are mandatory. The ECLM classification distinguishes recessive types 1 and 3 vWD from recessive vWD 2C due to mutations in the D1 and D2 domains and vWD 2N due to mutations in the D'-FVIII-binding domain of vWF. The ECLM classification differentiates between mild vWD type 1 with variable penetrance of bleedings from symptomatic dominant type 1 vWD secretion defect and/or clearance defect with normal vWF multimers versus vWD 1M and 2M with normal or smeary vWF multimers in low- and medium-resolution gels. High-quality multimeric analysis of vWF in medium-resolution gels based on a DDAVP challenge test clearly delineates and distinguishes each of the dominant type 2 vWDs 1/2E, 2M, 2B, 2A, and 2D caused by vWF gene mutations in the D3 multimerization domain, loss or gain-of-function mutations in the glycoprotein Ib receptor A1 domain, gene mutations in the A2 proteolytic domain, and the C-terminal dimerization domain, respectively.
- 650 _2
- $a desmopresin $x farmakologie $7 D003894
- 650 12
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a multimerizace proteinu $7 D055503
- 650 _2
- $a von Willebrandova nemoc, typ 1 $x diagnóza $7 D056725
- 650 _2
- $a von Willebrandova nemoc, typ 2 $x diagnóza $7 D056728
- 650 _2
- $a von Willebrandův faktor $x analýza $x genetika $7 D014841
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Smejkal, Petr $u 3 Department of Clinical Hematology, University Hospital, Masaryk University, Brno, Czech Republic. 4 Faculty of Medicine, Department of Laboratory Methods, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Penka, Miroslav $u 3 Department of Clinical Hematology, University Hospital, Masaryk University, Brno, Czech Republic. 4 Faculty of Medicine, Department of Laboratory Methods, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Batorova, Angelika $u 5 Department of Hemostasis and Thrombosis, National Hemophilia Center, Medical School of Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Pricangova, Tatiana $u 5 Department of Hemostasis and Thrombosis, National Hemophilia Center, Medical School of Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Budde, Ulrich $u 6 Central Laboratory, Asklepios Kliniken, Hamburg, Germany.
- 700 1_
- $a Vangenechten, Inge $u 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium. 8 Hemostasis Research Unit, Antwerp University Hospital, Antwerp, Belgium.
- 700 1_
- $a Gadisseur, Alain $u 2 Hemostasis Research Unit, Department of Hematology, Antwerp University Hospital, Belgium. 7 Department of Hematology, Antwerp University Hospital, Antwerp, Belgium. 8 Hemostasis Research Unit, Antwerp University Hospital, Antwerp, Belgium.
- 773 0_
- $w MED00001108 $t Clinical and applied thrombosis/hemostasis official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis $x 1938-2723 $g Roč. 23, č. 6 (2017), s. 518-531
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/27443694 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180713102915 $b ABA008
- 999 __
- $a ok $b bmc $g 1317475 $s 1022265
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 23 $c 6 $d 518-531 $e 20160721 $i 1938-2723 $m Clinical and applied thrombosis/hemostasis $n Clin Appl Thromb Hemost $x MED00001108
- LZP __
- $a Pubmed-20180709